Metis Global Partners LLC Sells 961 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Metis Global Partners LLC cut its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.8% during the fourth quarter, Holdings Channel reports. The firm owned 15,470 shares of the medical equipment provider’s stock after selling 961 shares during the quarter. Metis Global Partners LLC’s holdings in Intuitive Surgical were worth $5,219,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. OFI Invest Asset Management purchased a new stake in shares of Intuitive Surgical during the 3rd quarter valued at about $25,000. Baystate Wealth Management LLC lifted its position in Intuitive Surgical by 150.0% in the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 45 shares during the last quarter. MCF Advisors LLC boosted its stake in Intuitive Surgical by 108.1% during the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 40 shares during the period. Headinvest LLC purchased a new position in shares of Intuitive Surgical during the 3rd quarter worth about $28,000. Finally, Stone House Investment Management LLC grew its holdings in Intuitive Surgical by 100.0% during the 3rd quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 50 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Mizuho boosted their price objective on Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a report on Thursday, January 25th. Wells Fargo & Company increased their price objective on shares of Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research note on Friday, January 19th. StockNews.com lowered Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Stifel Nicolaus lifted their price target on Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a report on Monday, April 8th. Finally, Citigroup increased their price target on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $396.17.

Insider Activity at Intuitive Surgical

In other news, President David J. Rosa sold 80,710 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $389.28, for a total value of $31,418,788.80. Following the sale, the president now directly owns 163,399 shares of the company’s stock, valued at approximately $63,607,962.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Intuitive Surgical news, President David J. Rosa sold 80,710 shares of Intuitive Surgical stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $389.28, for a total transaction of $31,418,788.80. Following the completion of the transaction, the president now owns 163,399 shares in the company, valued at approximately $63,607,962.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total value of $78,400.00. Following the completion of the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at approximately $736,800. The disclosure for this sale can be found here. Insiders have sold a total of 226,928 shares of company stock worth $87,833,828 over the last quarter. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Up 1.0 %

Shares of ISRG traded up $3.71 during trading hours on Friday, reaching $381.36. 1,028,858 shares of the company traded hands, compared to its average volume of 1,492,254. The business has a fifty day moving average price of $385.40 and a 200-day moving average price of $350.34. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $403.76. The stock has a market capitalization of $135.27 billion, a P/E ratio of 68.84, a P/E/G ratio of 4.93 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm’s revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.00 EPS. As a group, research analysts predict that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.